Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Lyman GH"" wg kryterium: Autor


Tytuł :
Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá ; Survival and associated factors in children with Acute Lymphoid Leukemia in a reference center in Bogotá
Autorzy :
Castelblanco-Coy, Lizeth Johana
reponame:Repositorio Institucional EdocUR ; instname:Universidad del Rosario ; 1. Fondo Colombiano de Enfermedades de Alto Costo. Generalidades Cáncer Pediátrico. In: Situación del Cáncer en Colombia 2015. Fondo Colombiano de Enfermedades de Alto Costo; 2015. p. 73–90. ; 2. Bravo LE
García LS
Collazos P
Aristizabal P
Ramírez O. Descriptive epidemiology of childhood cancer in Cali
Colombia 1977-2011. Colomb Med. 2013;44(3):155–64. ; 3. Coebergh JWW
Reedijk AMJ
de Vries E
Martos C
Jakab Z
Steliarova-Foucher E
et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36. ; 4. Horibe K
Saito AM
Takimoto T
Tsuchida M
Manabe A
Shima M
et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): Based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98(1):74–88. ; 5. Ries L
Smith M
Gurney J
Linet M
Tamra T
Young J
et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. 1999. p. 1–182. ; 6. Miller R. Persons with exceptionally high risk of leukemia. Cancer Res. 1967;27:2420–2423. ; 7. Belson M
Kingsley B
Holmes A. Risk Factors for Acute Leukemia in Children: A Review. Environ Health Perspect. 2007;115(1):138–45. ; 8. Gardner MJ. Father’s occupational exposure to radiation and the raised level of childhood leukemia near the Sellafield nuclear plant. Environ Health Perspect. 1991;94:5–7. ; 9. McKinney PA
Alexander FE
Cartwright RA
Parker L. Parental Occupations Of Children With Leukaemia In West Cumbria
North Humberside
And Gateshead. Vol. 302
BMJ: British Medical Journal. BMJ; 1991. p. 681–7. ; 10. Shu XO
Stewart P
Wen W
Han D
Potter JD
Buckley JD
et al. Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring 1. Cancer Epidemiol biomarkers Prev. 1999;8:783–91. ; 11. Freedman DM
Kleinerman RA
Wacholder S
Hatch EE
Tarone RE
et al. Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health. 2001;91(4):564–7. ; 12. Pardo C
Cendales R. Incidencia
mortalidad y prevalencia de Cáncer en Colombia 2007-2011. 1st ed. Pardo C
Cendales R
editors. Vol. 1
Instituto Nacional De Cancerologia. Bogotá D.C.; 2015. 13–147 p. ; 13. Vera AM
Pardo C
Duarte MC
Suárez A. Experiencia en el análisis de la mortalidad por leucemia aguda pediátrica en el Instituto Nacional de Cancerología. Biomédica. 2012;32(3):355–64. ; 14. Linares Ballesteros A
Torres Amaya AM
Molina León HF
Vizcaíno Valderrama MP
Martínez Beltrán L
de Los Reyes Valencia I del C
et al. Guía de Práctica Clínica para la detección oportuna
diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños
niñas y adolescentes. Ministerio de Salud y Protección Social - Colciencias; 2013. p. 4–83. ; 15. World Health Organization. Global Cancer Observatory [Internet]. International Agency for Research on Cancer. 2020 [cited 2021 Feb 4]. Available from: https://gco.iarc.fr/ ; 16. Bosetti C
Bertuccio P
Chatenoud L
Negri E
Levi F
La Vecchia C. Childhood cancer mortality in Europe
1970-2007. Eur J Cancer. 2010;46(2):384–94. ; 17. Hunger SP
Winick NJ
Sather HN
Carroll WL. Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough? Pediatr Blood Cancer. 2005;45(7):876–80. ; 18. Magrath I
Steliarova-foucher E
Epelman S
Ribeiro RC
Harif M
Li C
et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14:e104–16. ; 19. Wayne AS
Reaman GH
Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008;100(18):1271–3. ; 20. Pui C-H
Carroll WL
Meshinchi S
Arceci RJ. Biology
Risk Stratification
and Therapy of Pediatric Acute Leukemias: An Update. J Clin Oncol. 2011;29(5):551–65. ; 21. Kato M
Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4–12. ; 22. Gatta G
Zigon G
Capocaccia R
Coebergh JW
Desandes E
Kaatsch P
et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6):992–1005. ; 23. Lightfoot TJ
Johnston WT
Simpson J
Smith AG
Ansell P
Crouch S
et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9. ; 24. Lustosa de Sousa DW
de Almeida Ferreira FV
Cavalcante Félix FH
de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: Prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223–9. ; 25. Piñeros M
Otero J
Suárez A
Vizcaíno M
Alvarez VH
et al. Protocolo de vigilancia en salud pública de las leucemias agudas pediátricas. Instituto Nacional de Salud Instituto Nacional de Cancerología Ministerio de la Protección social. 2007. p. 1–13. ; 26. Sarmiento-Urbina IC
Linares-Ballesteros A
Contreras-Acosta A
Cabrera-Bernal EV
Pardo-González CA
Uribe-Botero GI
et al. Resultados del Protocolo ACHOP 2006 en los niños con leucemia linfoblástica aguda en la Fundación HOMI Hospital de la Misericordia de Bogotá
en el periodo 2007 - 2012. IATREIA. 2019;32(2):71–81. ; 27. Cuenta de Alto Costo. Situación del cáncer de la población atendida en el SGSSS en Colombia 2015. Cuenta Alto Costo. 2016;1(1):35–330. ; 28. Nordlund J
Syvänen AC. Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol. 2018;51:129–38. ; 29. Iacobucci I
Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–83. ; 30. Lanzkowsky P. Leukemias. In: Lanzkowsky P
editor. Manual of Pediatric Hematology and Oncology. 5th ed. San Diego
California: ElSevier; 2011. p. 518–66. ; 31. Cooper SL
Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61–73. ; 32. Instituto Nacional de Cancerología. Protocolo de tratamiento de Leucemia Linfoblástica Aguda LLA - INC 2012 basado en LLA - PINDA IC 2009. 2012. p. 1–42. ; 33. Erker C
Yan K
Zhang L
Bingen K
Flynn KE
Panepinto J. Impact of pediatric cancer on family relationships. Cancer Med. 2018;7(5):1680–8. ; 34. Ruggiero A
Ferrara P
Attinà G
Rizzo D
Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol. 2017;83(12):2605–14. ; 35. Pui C-H
Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149–65. ; 36. Turcotte LM
Liu Q
Yasui Y
Arnold MA
Hammond S
Howell RM
et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer
1970-2015. JAMA - J Am Med Assoc. 2017;317(8):814–24. ; 37. Gaudichon J
Jakobczyk H
Debaize L
Cousin E. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56. ; 38. Irestorm E
Olsson IT
Johansson B
Øra I. Cognitive fatigue in relation to depressive symptoms after treatment for childhood cancer. BMC Psychol. 2020;8(31):1–9. ; 39. Steur LMH
Grootenhuis MA
Van Someren EJW
Van Eijkelenburg NKA
Van der Sluis IM
Dors N
et al. High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. Pediatr Blood Cancer. 2020;67(4):e28165. ; 40. Mody R
Li S
Dover DC
Sallan S
Leisenring W
Oeffinger KC
et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515–23. ; 41. The World Bank. World Bank Country and Lending Groups [Internet]. Working for a World Free of Poverty. 2020 [cited 2021 Feb 4]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 ; 42. Bravo L
Collazos T
García L
Gutiérrez A
Carrascal E. Cáncer infantil en Cali
Colombia
1994-2003. Registro Poblacional de Cáncer en Cali. Cali: Camilo Torres Serna y Cia S.C.S; 2009. ; 43. Abboud MR
Ghanem K
Muwakkit S. Acute lymphoblastic leukemia in low and middle-income countries: disease characteristics and treatment results. Curr Opin Oncon. 2014;26(6):650–5. ; 44. Conter V
Bartram CR
Valsecchi MG
Schrauder A
Panzer-Grümayer R
Möricke A
et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):1–24. ; 45. Rengifo LA
Suárez A. Protocolo de tratamiento de leucemia linfoblástica aguda LLA-INC 2012. Basado en LLA-PINDA 2009. Inst Nac Cancerol. 2012;1–42. ; 46. Campbell M
Luis C
Riccheri C
Janic D
Jazbec J
Kaiserova E
et al. Protocolo de estudio y tratamiento de la leucemia linfoblástica infantil. ALL IC-BFM 2009. Santiago de Chile: Ministerio de Salud de Chile; 2009. p. 1–174. ; 47. Ospina-Romero M
Portilla CA
Bravo LE
Ramirez O. Caregivers’ self-reported absence of social support networks is related to treatment abandonment in children with cancer. Pediatr Blood Cancer. 2016;63:825–31. ; 48. Shen S
Cai J
Chen J
Xue H
Pan C
Gao Y
et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018;36(July):679–88. ; 49. Downing JR
Shannon KM. Acute leukemia: A pediatric perspective. Cancer Cell. 2002;2(6):437–45 ; 50. Linet MS
Ries LAG
Smith MA
Robert E
Devesa SS. Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States. J Natl Cancer Institute. 1999;91(12):1051–8. ; 51. Terwilliger T
Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. ; 52. Hutter JJ. Childhood Leukemia. Pediatr Rev. 2010;31(6):234–41. ; 53. Hunger S
Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–52. ; 54. Hoshino A
Okuno Y
Migita M
Ban H
Yang X
Kiyokawa N
et al. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. J Clin Immunol. 2015;35(2):108–11. ; 55. Buchbinder D
Nugent DJ
Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis
current management
and emerging treatments. Appl Clin Genet. 2014;7:55–66 ; 56. Stieglitz E
Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4(4):270–90. ; 57. Ratnaparkhe M
Hlevnjak M
Kolb T
Jauch A
Maass KK
Devens F
et al. Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia. 2017;31(10):2048–56. ; 58. Varon R
Reis A
Henze G
Einsiedel HG V.
Sperling K
Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 2001;61(9):3570–2. ; 59. Adams M
Jenney M
Lazarou L
White R
Birdsall S
Staab T
et al. Acute Myeloid Leukaemia after Treatment for Acute Lymphoblastic Leukaemia in Girl with Bloom Syndrome. J Genet Syndr Gene Ther. 2014;4(8):1–12 ; 60. Werner-Favre C
Wyss M
Cabrol C
Felix F
Guenin R
Laufer D. Cytogenetic study in a mentally retarded child with Bloom syndrome and acute lymphoblastic leukemia. Am J Med Genet. 1984;18(2):215–221 ; 61. Wang Y
Sun Z
Xu Y. Carriage of NBN polymorphisms and acute leukemia risk. Int J Clin Exp Med. 2015;8(3):3769–76. ; 62. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3–4):214–21. ; 63. Online Mendelinan Inheritance in Man. Fanconi Anemia [Internet]. OMIM. 2019 [cited 2020 Feb 24]. Available from: https://omim.org/search/?index=entry&start=1&limit=10&sort=score+desc
+prefix_sort+desc&search=Fanconi+anemia ; 64. Qian M
Cao X
Devidas M
Yang W
Cheng C
Dai Y
et al. TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591–9. ; 65. Zawitkowska J
Odoj T
Drabko K
Zaucha-Prazmo A
Rudnicka J
Romiszewski M
et al. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report. Pediatr Hematol Oncol. 2017;34(4):1–8. ; 66. Xu H
Perez-Andreu V
Fan Y
et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013;105(10):733–42. ; 67. Malard F
Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62. ; 68. Kinlen L. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer. 1995;71:1–5. ; 69. Bartenhagen C
Fischer U
Korn K
Pfister SM
Gombert M
Chen C
et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102(5):e179–83. ; 70. Martín-Lorenzo A
Hauer J
Vicente-Dueñas C
Auer F
González-Herrero I
García-Ramírez I
et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. Cancer Discov. 2015;5(12):1328–43. ; 71. Greaves M. Infection
immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193–203 ; 72. Greaves MF
Alexander FE. An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia. 1993 Mar;7(3):349–60. ; 73. Swaminathan S
Klemm L
Park E
Papaemmanuil E
Ford A
Kweon S-M
et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015;16(7):766–74 ; 74. Baljevic M
Jabbour E
O’Brien S
Kantarjian H. Acute Lymphoblastic Leukemia. In: Kantarjian H
Wolff R
editors. The MD Anderson Manual of Medical Oncology. 3rd ed. New York City: McGraw-Hill; 2016. ; 75. Margolin JF
Steuber P
Poplack DG. Acute Lymphoblastic Leukemia. In: Pizzo PA
Poplack DG
editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott-Williams and Wilkins; 2006. ; 76. Robazzi TCMV
Silva LR
Mendonça N
Barreto JHS. Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents. Acta Gastroenterol Latinoam. 2008;38(2):126–32. ; 77. Stephanos K
Picard L. Pediatric Oncologic Emergencies. Emerg Med Clin N Am. 2018;36(3):527–35. ; 78. Margolin J
Rabin K
Poplack D. Acute lymphoblastic leukemia. In: Pizzo P
Poplack D
editors. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott
Williams and Wilkins; 2011. p. 518–65 ; 79. Hangai M
Watanabe K
Shiozawa R
Hiwatari M
Ida K
Takita J. Relapsed acute lymphoblastic leukemia with unusual multiple bone invasions: A case report. Oncol Lett. 2014;7(4):991–3. ; 80. Sherief LM
Azab SF
Zakaria MM
Kamal M
Aly MAE
Ali A
et al. Renal presentation in pediatric acute leukemia: Report of 2 cases. Med (United States). 2015;94(37):37–40. ; 81. Cho-Vega JH
Medeiros LJ
Prieto VG
Vega F. Leukemia cutis. Am J Clin Pathol. 2008;129(1):130–42. ; 82. Jarošová M
Holzerová M
Jedličková K
Mihál V
Zuna J
Starý J
et al. Importance of using comparative genomic hybridization to improve detection of chromosomal changes in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000;123(2):114–22. ; 83. Mrózek K
Harper DP
Aplan PD. Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2009;23(5):991–1010. ; 84. Sutor A
Mall V
Thomas K. Bleeding and thrombosis in children with acute lymphoblastic leukaemia
treated according to the ALL-BFM-90 protocol. Klin Pädiatrie. 1999 Jul 13;211(04):201–4 ; 85. Lauer S
Kirchner P
Camitta B. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Am J Pediatr Hematol Oncol. 1989;11(1):64–73. ; 86. Mahmoud HH
Rivera GK
Hancock ML
Krance RA
Kun LE
Behm FG
et al. Low leucocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329(5):314–9. ; 87. McIntosh S
Ritchey A. Diagnostic problems in cerebrospinal fluid of children with lymphoid malignancies. Am J Pediatr Hematol Oncol. 1986;8(1):28–31 ; 88. Ingram LC
Fairclough DL
Furman WL
Sandlund JT
et al. Cranial nerve palsy in childhood acute lymphoblastic leukemia and non‐Hodgkin’s lymphoma. Cancer. 1991;67(9):2262–8. ; 89. Smith M
Arthur D
Camitta B
Carroll AJ
Crist W
Gaynon P
et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24. ; 90. Gilchrist GS
Tubergen DG
Coccia PF
O’Brien RT
Waskerwitz MJ
et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol. 1994;12(12):2594–600. ; 91. Tubergen DG
Cullen JW
Boyett JM
Gilchrist GS
et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group study. J Clin Oncol. 1994;12(2):273–8. ; 92. Clarke M
Hann I
Harrison G
Masera G
Peto R
et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003 May 1;21(9):1798–809. ; 93. Bennett J
Catovsky D
Daniel M-T
Flandrin G
Galton D
Gralnick H
et al. (FAB Co- operative Group): Proposals for the classification of the acute leukaemias. Br J Haematol. 1976;33:451. ; 94. Bennett J
et al. (FAB Co- operative Group): The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol. 1981;47:553. ; 95. Linares-Ballesteros A. Guía de Práctica Clínica para la detección oportuna
niñas ya dolescentes. Ministerio de Salud y Protección Social; 2013. ; 96. Vizcaino M
Lopera J
Martínez L
De los Reyes I
Linares A. Clinical practice guidelines for early detection
diagnosis
treatment and monitoring of acute lymcytic leukemia in children and teenagers in a developing country. Pediatr Infect Dis Open Access. 2016;1(4):25. ; 97. Langebrake C
Reinhardt D
Ritter J. Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf. 2002;25(15):1057–77. ; 98. Leung W
Hudson M
Zhu Y
et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14(7):1185–90. ; 99. Zawitkowska J
Lejman M
Plonowski M
Bulsa J
et al. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia. In Vivo (Brooklyn). 2019;33:1333–9. ; 100. Krull KR. Dexamethasone and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(3):e28118. ; 101. Mulhern R
Kovnar E
Langston J
Carter M
Fairclough D
Leigh L
et al. Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status. J Clin Oncol. 1992;(10):1095–1102. ; 102. Mulhern R
Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy
24-Gy
or no cranial irradiation. J Clin Oncol1. 1991;(9):1348–1356. ; 103. Tanner J
Davies P. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317–329. ; 104. Marshall W
Tanner J. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;13–23. ; 105. Marshall W
Tanner J. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;291–303. ; 106. Schmiegelow K
Müller K
Mogensen SS
Mogensen PR
Wolthers BO
Stoltze UK
et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Research. 2017;6(444):1–14. ; 107. Halsey C
Buck G
Richards S
Vargha-khadem F
Hill F
Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4(1):42. ; 108. Waber DP
Mccabe M
Sebree M
Forbes PW
Adams H
Alyman C
et al. Neuropsychological Outcomes of a Randomized Trial of Prednisone Versus Dexamethasone in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2013;60:1785–91. ; 109. Sun Y
Long S
Liu W. Observation of the molecular genetics among children with acute lymphoblastic leukemia: A retrospective study based on the SEER database. Medicine (Baltimore). 2020;99(21):e20009. ; 110. Lund B
Asberg A
Heyman M
Kanerva J
Harila-Saari A
Hasle H
et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56:551–9. ; 111. Paulsson K
Lilljebjörn H
Biloglav A
Olsson L
Rissler M
Castor A
et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672–6. ; 112. Pui C
Rebora P
Schrappe M
Attarbaschi A
Baruchel A. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019;37(10):770–9. ; 113. Andersson AK
Ma J
Wang J
Chen X
Gedman AL
Dang J
et al. The landscape of somatic mutations in infant MLL -rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–7. ; 114. Schultz K
Carroll A
Heeerema N
Bowman W
Slayton W
Sather H
et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467–71. ; 115. Johnston WT
Lightfoot TJ
Roman E. Childhood cancer survival: A report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol. 2010;34(6):659–66. ; 116. Barr RD
Klussman FA
Baez F
Bonilla M
Moreno B
Navarrete M
et al. Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A Model for Sustainable Development in Pediatric Oncology. Pediatr Blood Cancer. 2014;61:345–54. ; 117. Suarez A
Piña M
Nichols-Vinueza DX
Rengifo L
Mesa M
et al. A Strategy to Improve Treatment-Related Mortality and Abandonment of Therapy for Childhood ALL in a Developing Country Reveals the Impact of Treatment Delays. Pediatr Blood Cancer. 2015;62(March):1395–402. ; 118. Freeman D. Applied categorical data analysis. New York: Dekker
Inc; 1987. ; 119. RAE. Real Academia Española [Internet]. 2018 [cited 2018 Sep 21]. Available from: http://dle.rae.es/?id=XlApmpe ; 120. De la Asociación Médica Mundial sobre principios éticos para las investigaciones médicas en seres humanos. Declaración de Helsinki. 59a Asamblea General. 2008. ; 121. Ministerio de Salud. Resolución 8430 de 1993. Colombia; 1993 p. 1–19. ; 122. Congreso de Colombia. Ley estatutaria No. 1581. 17 Octubre 2012. Colombia; 2012 p. 1–301. ; 123. Conter V
et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):3206–14. ; 124. Campbell M. ALL IC-BFM 2009 A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia. 2009. 178 p. ; 125. Malo D
Pulido A. Infección Respiratoria Aguda
Colombia 2017. Instituto Nacional de Salud. 2017. p. 1–31. ; 126. Bartenhagen C
Pfister S
et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102:e179. ; 127. Lightfoot TJ
et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9. ; 128. Pui C-H
Dodge RK
Dahl G V
Rivera G
Look AT
Kalwinsky D
et al. Serum Lactic Dehydrogenase Level Has Prognostic Value in Childhoold Acute Lymphoblastic Leukemia. Blood. 1985;66(4):778–82. ; 129. Murali N
Swamy M
Prasad H
Saha D
Kini J
Kumar N. Significance of serum lactate dehydrogenase in childhood acute Lymphoblastic Leukaemia. J Clin Diagnostic Res. 2017;11(11):XC01–2. ; 130. Cairo MS
Coiffier B
Reiter A
Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86. ; 131. Basu SK
Fernandez ID
Fisher SG
Asselin BL
Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958–66. ; 132. Ramot B
Magrath I. Hypothesis: the environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukaemia in children. Br J Haematol. 1982;50(2):183–9. ; 133. Filippini T
Rothman KJ
Heck JE
Park AS
Crippa A
et al. Association between Outdoor Air Pollution and Childhood Leukemia: A Systematic Review and Dose-Response Meta-Analysis. Environ Health Perspect. 2019;127(4):46002. ; 134. Wakeford R. Childhood leukemia following medical diagnostic exposre to ionizing radiation in utero or after birth. Radiat Prot Dosimetry. 2008;132(2):166–74. ; 135. Cangerana F
Mirra A
Dias de Oliveira M do R
Pokaż więcej
Temat :
Leucemia Linfoide Aguda (LLA) en niños
Estudios de sobrevida a la LLA en países de ingreso mediano-alto
Estimación de curvas de sobrevida con el método Kaplan-Meier
Enfermedades
Acute Lymphoid Leukemia (ALL) in Children
Survival studies for ALL in upper-middle-income countries
Estimation of survival curves with the Kaplan-Meier method
Źródło :
reponame:Repositorio Institucional EdocUR ; instname:Universidad del Rosario ; 1. Fondo Colombiano de Enfermedades de Alto Costo. Generalidades Cáncer Pediátrico. In: Situación del Cáncer en Colombia 2015. Fondo Colombiano de Enfermedades de Alto Costo; 2015. p. 73–90. ; 2. Bravo LE, García LS, Collazos P, Aristizabal P, Ramírez O. Descriptive epidemiology of childhood cancer in Cali, Colombia 1977-2011. Colomb Med. 2013;44(3):155–64. ; 3. Coebergh JWW, Reedijk AMJ, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur ....
Opis pliku :
application/pdf
Relacje :
https://repository.urosario.edu.co/handle/10336/30971
Dostępność :
https://repository.urosario.edu.co/handle/10336/30971
Dysertacja/Praca dyplomowa
Tytuł :
Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation
Autorzy :
Bower, JE
Bak, K
Berger, A
Breitbart, W
Escalante, CP
Ganz, PA
Schnipper, HH
Lacchetti, C
Ligibel, JA
Lyman, GH
Ogaily, MS
Pirl, WF
Jacobsen, PB
Bower
JE; Bak
K; Berger
A; Breitbart
W; Escalante
CP; Ganz
PA; et al.(2014). Screening
assessment
and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. Journal of Clinical Oncology
32(17)
Pokaż więcej
Time :
1840 - 1850
Źródło :
Bower, JE; Bak, K; Berger, A; Breitbart, W; Escalante, CP; Ganz, PA; et al.(2014). Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. Journal of Clinical Oncology, 32(17), 1840 - 1850. doi:10.1200/JCO.2013.53.4495. UCLA: Retrieved from: http://www.escholarship.org/uc/item/6qk4b457
Opis pliku :
application/pdf
Relacje :
qt6qk4b457; http://www.escholarship.org/uc/item/6qk4b457
Dostępność :
https://doi.org/10.1200/JCO.2013.53.4495
http://www.escholarship.org/uc/item/6qk4b457
Czasopismo naukowe
Tytuł :
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with Venous Thromboembolism: Results of a randomized trial (SELECT-D)
Autorzy :
Young, AM
Marshall, A
Thirlwall, J
Chapman, O
Lokare, A
Hill, C
Hale, D
Dunn, JA
Lyman, GH
Hutchinson, C
MacCallum, P
Kakkar, A
Hobbs, FDR
Petrou, S
Dale, J
Poole, CJ
Maraveyas, A
Levine, M
Pokaż więcej
Relacje :
urn:uuid:d90c1698-c095-49d2-9c7a-5ade3a5404f3; uuid:d90c1698-c095-49d2-9c7a-5ade3a5404f3; d90c1698-c095-49d2-9c7a-5ade3a5404f3; pubs:862757; eissn:1527-7755; https://doi.org/10.1200/jco.2018.78.8034
Dostępność :
https://doi.org/10.1200/jco.2018.78.8034
Czasopismo naukowe
Tytuł :
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Autorzy :
Young, AM
Marshall, A
Thirlwall, J
Chapman, O
Lokare, A
Hill, C
Hale, D
Dunn, JA
Lyman, GH
Hutchinson, C
MacCallum, P
Kakkar, A
Hobbs, FDR
Petrou, S
Dale, J
Poole, CJ
Maraveyas, A
Levine, M
Pokaż więcej
Opis pliku :
2017 - 2023
Relacje :
J Clin Oncol; http://qmro.qmul.ac.uk/xmlui/handle/123456789/41063
Dostępność :
https://doi.org/10.1200/JCO.2018.78.8034
http://qmro.qmul.ac.uk/xmlui/handle/123456789/41063
Czasopismo naukowe
Tytuł :
Factores de riesgo asociados a ingreso a UCIP en pacientes con neutropenia febril ClÍnica Prevenir Barranquilla enero – junio de 2018
Autorzy :
Robledo De La Hoz, Tito Isaac
Parodi Saltaren, Carlos José
reponame:Repositorio Institucional Universidad Libre ; instname:Universidad Libre ; Pérez J. Neutropenia febril en pediatría. CCAP Precob SCP. 2011. (12)1:33-45. ; Lane S
Kohler J. The management of febrile neutropenia. Current Paediatrics 2005; 15: 400-405 ; Phillips RS
Wade R
Lehrnbecher T
Stewart L a
Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC medicine. BioMed Central Ltd; 2012 Jan;10(1):6. ; Navarrro J
Sanchez W. Factores de riesgo de ingreso a UCI en pacientes con neutropenia febril
Clínica prevenir Barranquilla y Fundación Hospital Universitario Metropolitano
enero – octubre de 2011. Tesis de grado UniMetro. 2012. ; Santolaya ME
Rabagliati R
Bidart T
Paya E
Guzman AM
Morales R et al. [Consensus: Rational approach towards the patient with cancer
fever and neutropenia]. Rev Chilena Infectol 2005;22 Suppl 2:S79-113 ; Freifeld AG
Bow EJ
Sepkowitz KA
Boeckh MJ
Ito JI
Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 February 15;52(4):e56-e93 ; Jaramillo C
Valencia I
Aristizábal M. Neutropenia febril en pacientes pediátricos: un enfoque diagnóstico y terapéutico Iatreia
2009; 22(3): 235-245 ; Lai HP
Hsueh PR
Chen YC
Lee PI
Lu CY
Lu MY
et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect 2003; 36: 197-202. ; Hughes WT
Armstron D
Bodey GP
Brown EA
Calandra T
et al. 2002 Guidelines for the use for antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51. ; Amman RA
Aebi C
Hirt A. Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center
1993-2001. Support Care Cancer. 2004. (12):826-32 ; López P
López E. Neutropenia febril en pediatría. Infectio 2008;12(1):64-71. ; Rincón C. Caracterización de episodios de neutropenia febril en niños con cáncer en la Fundación Hospital de la Misericordia. Uni Nacional. 2013; 1-71 ; Comité Nacional de Infectología Pediátrica. [Consensus on management of children with cancer
neutropenia and fever: Update 2008-2009]. Archivos argentinos de pediatría. 2010;108(2):e47–70. ; De Naurois J
Novitzky-Basso I
Gill MJ
Marti FM
Cullen MH
Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 (5):v252–6. ; Guzmán P
Ruiz J. Neutropenia febril en Pediatría: ¿qué punto de corte usar?. Pediatría. 2012; 45(3):195-202 ; Lucas KG
Brown AE
Armstrong D
Chapman D
Heller G. The identification of febrile
neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer. 1996;77(4):791-8. ; Bate J
Gibson F
Johnson E
Selwood K
Skinner R
Chisholm J
et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of disease in childhood Education and practice edition. 2013;98(2):73-5 ; Departamento de estadistica
Clínica Prevenir Bonadonna
2017 ; Hughes WT
Calandra T. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51 ; Paganini H
Santolaya E
Álvarez M
Araña M
Arteaga R
Bonilla A et al. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: Consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Rev. chil. infectol. 2011; 28(1):10-38. ; Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities change of the currently isolated pathogens. Clin Infect Dis 2004; 39: S25-S31. ; Marchetti O
Calandra T. Infections in neutropenic cancer patients. Lancet 2002; 359: 723-5 ; Yadegarynia D
Tarrand J
Raad I
Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37: 1144-5 ; Laurichesse H
Romaszko JP
Nguyen LT
Souweine B
Poirier V
Guólon D. Clinical characteristics and outcome of patients with invasive pneumococcal disease Puy de Dóme France1994-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 299-308 ; Zaoutis TE
Roilides E
Chiou CC
Buchanan WL
Knudsen TA
Sarkisova TA. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-7 ; Velasco E
Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8 ; Ramphal R
Grant RM
Dzolganovski B
Constantin J
Tellier R
Allen U. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26: 700-4 ; Tager FM
Zolezzi RP
Folatre BI
Navarrete CM
Rojas PJ. Respiratory virus infections in children with acute lymphoblastic leukemia and febrile neutropenia: a prospective study. Rev Chil Infectol 2006; 23: 118-23 ; Rackoff W
Gonin R
Robinson C
Kreissman SG
Breitfeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-24 ; Klaasen RJ
Goodman TR
Pham B
Doyle JJ. Low risk prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-9 ; Santolaya ME
Alvarez A
Becker A
Cofré J
Enríquez N
O'Ryan M. Prospective
multicenter evaluation of risk factors associated with invasive bacterial 36 infection in children with cáncer
neutropenia and fever. J Clin Oncol 2001; 19: 3415-21 ; Santolaya ME
Avilés CL
Enríquez N. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer
fever and neutropenia. Clin Infect Dis 2002; 35: 67883 ; Santolaya ME
Alvarez AM
King A
Mosso C. Predictors of severe sepsis not clinically apparent during the first twenty four hours of hospitalization in children with cancer neutropenia and fever: a prospective multicenter trial. Pediatr Infect Dis J 2008; 27: 538-43 ; Basu SK
Fernández ID
Fisher SG
Asselin BL
Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23: 7958-66 ; Paganini H
Aguirre C
Puppa G
Garbini C
Javier R G
Ensinck G. A prospective
multicentric screening system to predict mortality in febrile neutropenic children with cancer. Cancer 2007; 109: 2572-9 ; Santolaya ME
Mosso C. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenia episode. Pediatr Infect Dis J 2007; 26: 794-8 ; Rivas R. Consenso mexicano para el abordaje diagnóstico y terapéutico del paciente con neutropenia febril. Rev Hematol Mex 2014;15 (2):207-268 ; Suárez D
Gómez J
Carrasco M
Burbano D. Caracterización clínica y de laboratorio de pacientes con neutropenia febril en un hospital pediátrico en Pasto-Colombia. Pediatr. 2016;49(2):48–53 ; Vizcaíno H. Caracterización clínica y epidemiológica de los pacientes pediátricos oncológicos con neutropenia febril. Uni de Cartagena
Pokaż więcej
Temat :
Neutropenia
Instituciones de salud
Cuidados intensivos pediátricos
Hospitales -- Administración de riesgos
Health institutions
Hospitals - Risk Management
Pediatric intensive care
Neutropenia maligna -- Investigaciones -- Barranquilla (Colombia)
Hospitales – Administración de riesgos
Źródło :
reponame:Repositorio Institucional Universidad Libre ; instname:Universidad Libre ; Pérez J. Neutropenia febril en pediatría. CCAP Precob SCP. 2011. (12)1:33-45. ; Lane S, Kohler J. The management of febrile neutropenia. Current Paediatrics 2005; 15: 400-405 ; Phillips RS, Wade R, Lehrnbecher T, Stewart L a, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC medicine. BioMed Central Ltd; 2012 Jan;10(1):6. ; Navarrro J, Sanchez W. Factores de riesgo de ingreso a UCI en pacientes con neutropenia febril, Clínica prevenir Barranquilla y ....
Opis pliku :
PDF; application/pdf
Relacje :
http://hdl.handle.net/10901/17742
Dostępność :
http://hdl.handle.net/10901/17742
Dysertacja/Praca dyplomowa
Tytuł :
Caracterización de los pacientes que ingresan a ucip por neutropenia febril. clinica prevenir Barranquilla 2015 - 2016
Autorzy :
Medina Caicedo, Malvin
Ramos Castro, José
instname:Universidad Libre ; reponame:Repositorio Institucional Unilibre ; Pérez J. Neutropenia febril en pediatría. CCAP Precob SCP. 2011. (12)1:33-45 ; Jaramillo C
Valencia I
Aristizábal M. Neutropenia febril en pacientes pediátricos: un enfoque diagnóstico y terapéutico Iatreia
2009; 22(3): 235-245 ; López P
López E. Neutropenia febril en pediatría. Infectio 2008;12(1):64-71. ; Comité Nacional de Infectologia Pediátrica. [Consensus on management of children with cancer
neutropenia and fever: Update 2008-2009]. Archivos argentinos de pediatría. 2010;108(2):e47–70. ; Guzmán P
Ruiz J. Neutropenia febril en Pediatría: ¿qué punto de corte usar?. Pediatría. 2012; 45(3):195-202 ; Rincón C. Caracterización de episodios de neutropenia febril en niños con cáncer en la Fundación Hospital de la Misericordia. Uni Nacional. 2013; 1-71 ; Departamento de estadística
Clínica Prevenir Bonadonna
2016. ; Paganini H
Santolaya E
Álvarez M
Araña M
Arteaga R
Bonilla A et al. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: Consenso de la Sociedad Latinoamericana de Infectologia Pediátrica. Rev. chil. infectol. 2011; 28(1):10-38. ; Zaoutis TE
Roilides E
Chiou CC
Buchanan WL
Knudsen TA
Sarkisova TA. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-7 ; Rackoff W
Gonin R
Robinson C
Kreissman SG
Breitfeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-24 ; Rivas R. Consenso mexicano para el abordaje diagnóstico y terapéutico del paciente con neutropenia febril. Rev Hematol Mex 2014;15 (2):207-268 ; Suárez A
Casas C
González O. Asociación entre el tiempo para iniciar la administración de los antibióticos y desenlaces en pacientes con neutropenia febril. Tesis Unimilitar Nueva Granada. 2016: 1-34 ; Suárez D
Gómez J
Carrasco M
Burbano D. Caracterización clínica y de laboratorio de pacientes con neutropenia febril en un hospital pediátrico en Pasto-Colombia. Pediatr. 2016;49(2):48–53 ; Vizcaíno H. Caracterización clínica y epidemiológica de los pacientes pediátricos oncológicos con neutropenia febril. Uni de Cartagena
2014:1-24 ; Navarrro J
Sánchez W. Factores de riesgo de ingreso a UCI en pacientes con neutropenia febril
Clínica prevenir Barranquilla y Fundación Hospital Universitario Metropolitano
enero – octubre de 2011. Tesis de grado UniMetro. 2012. ; Lane S
Kohler J. The management of febrile neutropenia. Current Paediatrics 2005; 15: 400-405 ; Santolaya ME
Rabagliati R
Bidart T
Paya E
Guzman AM
Morales R et al. [Consensus: Rational approach towards the patient with cancer
fever and neutropenia]. Rev Chilena Infectol 2005;22 Suppl 2:S79-113 ; Freifeld AG
Bow EJ
Sepkowitz KA
Boeckh MJ
Ito JI
Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 February 15;52(4):e56-e93 ; Lai HP
Hsueh PR
Chen YC
Lee PI
Lu CY
Lu MY
et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect 2003; 36: 197-202. ; Hughes WT
Armstron D
Bodey GP
Brown EA
Calandra T
et al. 2002 Guidelines for the use for antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51. ; Amman RA
Aebi C
Hirt A. Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center
1993-2001. Support Care Cancer. 2004. (12):826-32 ; De Naurois J
Novitzky-Basso I
Gill MJ
Marti FM
Cullen MH
Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 (5):v252–6. ; Lucas KG
Brown AE
Armstrong D
Chapman D
Heller G. The identification of febrile
neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer. 1996;77(4):791-8. ; Bate J
Gibson F
Johnson E
Selwood K
Skinner R
Chisholm J
et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of disease in childhood Education and practice edition. 2013;98(2):73-5 ; Hughes WT
Calandra T. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51 ; Phillips RS
Wade R
Lehrnbecher T
Stewart L a
Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC medicine. BioMed Central Ltd; 2012 Jan;10(1):6. ; Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities change of the currently isolated pathogens. Clin Infect Dis 2004; 39: S25-S31. ; Marchetti O
Calandra T. Infections in neutropenic cancer patients. Lancet 2002; 359: 723-5 ; Yadegarynia D
Tarrand J
Raad I
Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37: 1144-5 ; Laurichesse H
Romaszko JP
Nguyen LT
Souweine B
Poirier V
Guólon D. Clinical characteristics and outcome of patients with invasive pneumococcal disease Puy de Dóme France1994-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 299-308 ; Velasco E
Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8 ; Ramphal R
Grant RM
Dzolganovski B
Constantin J
Tellier R
Allen U. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26: 700-4 ; Tager FM
Zolezzi RP
Folatre BI
Navarrete CM
Rojas PJ. Respiratory virus infections in children with acute lymphoblastic leukemia and febrile neutropenia: a prospective study. Rev Chil Infectol 2006; 23: 118-23 ; Klaasen RJ
Goodman TR
Pham B
Doyle JJ. Low risk prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-9 ; Santolaya ME
Alvarez A
Becker A
Cofré J
Enríquez N
O'Ryan M. Prospective
multicenter evaluation of risk factors associated with invasive bacterial infection in children with cáncer
neutropenia and fever. J Clin Oncol 2001; 19: 3415-21 ; Santolaya ME
Avilés CL
Enríquez N. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer
fever and neutropenia. Clin Infect Dis 2002; 35: 678- 83 ; Santolaya ME
Alvarez AM
King A
Mosso C. Predictors of severe sepsis not clinically apparent during the first twenty four hours of hospitalization in children with cancer neutropenia and fever: a prospective multicenter trial. Pediatr Infect Dis J 2008; 27: 538-43 ; Basu SK
Fernández ID
Fisher SG
Asselin BL
Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23: 7958-66. ; Paganini H
Aguirre C
Puppa G
Garbini C
Javier R G
Ensinck G. A prospective
multicentric screening system to predict mortality in febrile neutropenic children with cancer. Cancer 2007; 109: 2572-9. ; Santolaya ME
Pokaż więcej
Temat :
Caracterización epidemiológica
Neutropenia febril
Foco infeccioso
Epidemiological characterization
Febrile neutropenia
Infectious focus
Vigilancia Epidemiológica
Źródło :
instname:Universidad Libre ; reponame:Repositorio Institucional Unilibre ; Pérez J. Neutropenia febril en pediatría. CCAP Precob SCP. 2011. (12)1:33-45 ; Jaramillo C, Valencia I, Aristizábal M. Neutropenia febril en pacientes pediátricos: un enfoque diagnóstico y terapéutico Iatreia, 2009; 22(3): 235-245 ; López P, López E. Neutropenia febril en pediatría. Infectio 2008;12(1):64-71. ; Comité Nacional de Infectologia Pediátrica. [Consensus on management of children with cancer, neutropenia and fever: Update 2008-2009]. Archivos argentinos de pediatría. 2010;108(2):e47–70. ; Guzmán P, Ruiz J. Neutropenia febril en Pediatría: ¿qué punto de corte usar?. Pediatría. 2012; 45(3):195-202 ; Rincón C. Caracterización de episodios de neutropenia febril ....
Opis pliku :
PDF
Relacje :
http://hdl.handle.net/10901/10721
Dostępność :
http://hdl.handle.net/10901/10721
Dysertacja/Praca dyplomowa
Tytuł :
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer
Autorzy :
Yate Cruz, José Alexander
Puentes Díaz, Andrea Liliana
reponame:Repositorio Institucional EdocUR ; instname:Universidad del Rosario ; Mosarla RC
Vaduganathan M
Qamar A
Moslehi J
Piazza G
Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73(11):1336–49 ; Karimi M
Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78–82 ; Khorana A
Francis C
Culakova E
Kuderer N
Lyman G. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost [Internet]. 2007;5:632–4. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L46680709%0Ahttp://dx.doi.org/10.1111/j.1538-7836.2007.02374.x%0Ahttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=15387933&id=doi:10.1111%2Fj.1538-7836.2007.02374.x&atitle=Thromboemb ; Puurunen MK
Gona PN
Larson MG
Murabito JM
Magnani JW
O’Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res [Internet]. 2016;145:27–33. Available from: http://dx.doi.org/10.1016/j.thromres.2016.06.033 ; Prandoni P
Lensing AWA
Piccioli A
Bernardi E
Simioni P
Girolami B
et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood [Internet]. 2002;100(10):3484–8. Available from: https://www.mendeley.com/catalog/identification-specific-inhibitor-histone-methyltransferase-suvar39-2/ ; Es N van
Blekera SM
Nisio M Di. Cancer-associated unsuspected pulmonary embolism. Thromb Res [Internet]. 2014;133:S172–8. Available from: http://dx.doi.org/10.1016/S0049-3848(14)50028-X ; Lee AYY
Levine MN
Baker RI
Bowden C
Kakkar AK
Prins M
et al. Low-Molecular-Weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53 ; Streiff M
Holmstrom B
Angelini D
Ashrani A
Bockenstedt PL
Chesney C
et al. Cancer-associated venous thromboembolic disease - NCCN guidelines version 1.2019. 2019 ; Kearon C
Akl EA
Comerota AJ
Prandoni P
Bounameaux H
Goldhaber SZ
et al. Antithrombotic therapy and prevention of thrombosis
9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e419S-e494S ; Cristina M
Giustozzi M
Bonitta G
Agnelli G
Becattini C. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer : A network meta-analysis. Thromb Res. 2018;170:175–80 ; Young AM
Marshall A
Thirlwall J
Chapman O
Lokare A
Hill C
et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23 ; Khorana AA
Dalal MR
Lin J
Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clin Outcomes Res. 2013;5:101–8 ; Dennis R. Estudio nacional sobre tromboembolismo venoso en población hospitalaria en Colombia. Acta Med … [Internet]. 1996;21:55–63. Available from: http://actamedicacolombiana.com/anexo/articulos/02-1996-02-Estudio_nacional_sobre_tromboembolismo_venoso_en.pdf ; Denis RJ
Rojas MX
Molina Á
Roa J
Granados M
Londoño A
et al. Curso clínico y supervivencia en embolia pulmonar. Resultados del registro multicéntrico colombiano (EMEPCO). Acta médica Colomb. 2008;33(3):111–6 ; Perilla O. Caracterización clínica de pacientes con enfermedad tromboembólica asociada a cáncer en el Instituto Nacional de Cancerología. 2018 ; Verso M
Franco L
Becattini C
Agnelli G. Treatment of venous thromboembolism in patients with cancer: what news from clinical trials? Thromb Res. 2018;164:S168–71 ; Noble S
Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer [Internet]. 2010;102(S1):S2–9. Available from: http://dx.doi.org/10.1038/sj.bjc.6605599 ; Kearon C
Ornelas J
Blaivas A
Jimenez D
et al. Antithrombotic therapy for VTE disease - CHEST guideline and expert panel report. Chest. 2016;149(2):315–52 ; Lyman GH
Bohlke K
Khorana AA
Kuderer NM
Lee AY
Arcelus JI
et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–7 ; Khorana AA
Yannicelli D
McCrae KR
Milentijevic D
Crivera C
Nelson WW
et al. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51–3 ; Siwan S
Nelson A
Noble S. Cancer-associated thrombosis
low-molecular-weight heparin
and the patient experience: a qualitative study. Patient Prefer Adherence. 2014;8:453–61 ; Ross JA
Miller MM
Rojas Hernandez C. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res. 2017;150:86–9 ; Moreno M
Mejía A
Héctor C. Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológica en Salud – IETS. 2014. 1–33 p ; Deng A
Galanis T
Graham MG. Venous thromboembolism in cancer patients. Hosp Pract (1995). 2014;42(5):24–33 ; Blom JW
Doggen CJM
Osanto S
Rosendaal FR. Malignancies
prothrombotic mutations
and the risk of venous thrombosis. JAMA. 2005;293(6):715–22 ; Heit JA
Silverstein MD
Mohr DN
Petterson TM
O’Fallon WM
Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160:809–17 ; Timp JF
Braekkan SK
Versteeg HH
Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23 ; Harvey D
Zhou H
Chew HK
Wun T
White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64 ; Walker AJ
Card TR
West J
Crooks C
Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer [Internet]. 2013;49:1404–13. Available from: http://dx.doi.org/10.1016/j.ejca.2012.10.021 ; Horsted F
Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. Plos Med. 2012;9(7):1–19 ; Gussoni G
Frasson S
La Regina M
Di Micco P
Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res [Internet]. 2013;131:24–30. Available from: http://dx.doi.org/10.1016/j.thromres.2012.10.007 ; Cronin-Fenton DP
Søndergaard F
Pedersen LA
Fryzek JP
Cetin K
Acquavella J
et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark
1997-2006. Br J Cancer. 2010;103:947–53 ; Khorana AA
Francis CW
Lyman GH. Frequency
risk factors
and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46 ; Agnelli G
Bolis G
Capussotti L
Scarpa RM
Tonelli F
Bonizzoni E
et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg [Internet]. 2006;243(1):89–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16371741%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1449979 ; Blom JW
Vanderschoot JPM
Oostindiër MJ
Van Der Meer FJM
Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529–35 ; Falanga A
Russo L
Milesi V
Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83 ; Fernandes CJ
Morinaga LTK
Jr JLA
Castro MA
Calderaro D
Jardim CVP
et al. Cancer-associated thrombosis : the when
how and why. 2019;28:1–11. Available from: http://dx.doi.org/10.1183/16000617.0119-2018 ; Elyamany G
Alzahrani AM
Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129–37 ; Mukai M
Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72:89–93 ; Kakkar AK
DeRuvo N
Chinswangwatanakul V
Tebbutt S
Williamson RCN. Extrinsic-pathway activation in cancer with high factor Vlla and tissue factor. Lancet. 1995;346:1004–5 ; Nadir Y
Brenner B. Heparanase procoagulant activity in cancer progression. Thromb Res. 2016;140S1:S44–8 ; Falanga A
Tartari CJ
Marchetti M. Microparticles in tumor progression. Thromb Res [Internet]. 2012;129(Suppl.1):S132–6. Available from: http://dx.doi.org/10.1016/S0049-3848(12)70033-6 ; Wun T
White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk Factors. Cancer Invest. 2009;27(S1):63–74 ; Khorana AA
Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–47 ; Fernandes CJ
Alves JL
et al. Cancer-associated thrombosis: the when
how and why. Eur Respir Rev [Internet]. 2019;28:1–11. Available from: http://dx.doi.org/10.1183/16000617.0119-2018 ; Chew HK
Davies AM
Harvey D
White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601–8 ; Blom J. W
Osanto S.
Rosendaal F. R. The risk of a venous thrombotic event in lung cancer patients : higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760–5 ; Kroger K
Weiland D
Ose C
Neumann N
Weiss S
Hirsch C
et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303 ; Starling N
Rao S
Cunningham D
Iveson T
Nicolson M
Coxon F
et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline
platinum
and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2019;27(23):3786–93 ; Scappaticci FA
Skillings JR
Holden SN
Gerber H
Miller K
Kabbinavar F
et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and Bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9 ; Nalluri SR
Chu D
Keresztes R
Zhu X
Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab. JAMA. 2008;300(19):2277–85 ; Bohlius J
Wilson J
Seidenfeld J
Piper M
Schwarzer G
Sandercock J
et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708–14 ; Lee AYY
Butler G
Webb C
Costantini L
Gu C
et al. Incidence
and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404–8 ; Hisada Y
Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–506 ; Khorana AA
Ahrendt SA
Ryan CK
Hruban RH
Hu YC
et al. Tissue factor expression
angiogenesis
and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13(10):2870–6 ; Sallah S
Husain A
Sigounas V
Wan J
Turturro F
Sigounas G
et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004;10:7238–43 ; Ay C
Simanek R
Vormittag R
Dunkler D
Alguel G
Koder S
et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients : results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2019;112(7):2703–9 ; Khorana AA
Lyman GH
Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–8 ; Ay C
Marosi C
Chiriac A
et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–83 ; Oppelt P
Betbadal A
Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015;20(2):153–61 ; Verso M
Barni S
Gasparini G
LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy : the Protecht score. Intern Emerg Med. 2012;7:291–2 ; Agnelli G
Gussoni G
Bianchini C
Verso M
Mandalà M
Cavanna L
et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy : a randomised
placebo-controlled
double-blind study. Lancet Oncol [Internet]. 2009;10:943–9. Available from: http://dx.doi.org/10.1016/S1470-2045(09)70232-3 ; Agnelli G
George DJ
Fisher W
Lassen MR
Mismetti P
et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–10 ; M. DN
E. P
M. C
M. DT
I. R
AWS R. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review). Cochrane Libr. 2016;(12):1–164 ; Bergqvist D
Cohen AT
Eldor A
Nilson PE
Moigne-Amrani AL
et al. Duration of prophylaxis against venous thromboembolism with Enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–81 ; Carrier M
Abou-Nassar K
Mallick R
Tagalakis V
Shivakumar S
Schattner A
et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–9 ; Khorana AA
Soff GA
Vadhan-Raj S
Riess H
et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–8 ; Lee AYY
Kamphuisen PW
Meyer G
Bauersachs R
Janas MS
Jarner MF
et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–86 ; Agnelli G
Berkowitz S
(Chair) HB
Cohen A
Gallus A
et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510 ; Mismetti P
Schellong S
Eriksson H
Baanstra D
Sc M
Schnee J
et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;36(24):2342–52 ; Raskob GE
van Es N
Verhamme P
Carrier M
Di Nisio M
Garcia D
et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med [Internet]. 2018;378(7):615–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29231094 ; Agnelli G
Buller HR
Gallus AS
Lee TC
Pak R
et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients : results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91 ; Schulman S
et al. Treatment of Acute Venous Thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72 ; Agnelli G
et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97 ; Carrier M
Cameron C
Delluc A
Castellucci L
Lee AYY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis : a systematic review and meta-Analysis. Thromb Res [Internet]. 2019;134:1214–9. Available from: http://dx.doi.org/10.1016/j.thromres.2014.09.039 ; Key NS
Lee AYY
et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline ppdate. J Clin Oncol. 2019 ; Prins MH
Brighton TA
Lyons RM
Rehm J
Trajanovic M
et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37–46 ; Schulman S
Kearon C
et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114(1):150–7 ; Melloni C
Dunning A
Granger CB
Thomas L
Khouri MG
Garcia DA
et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med [Internet]. 2017;130:1440–8. Available from: https://doi.org/10.1016/j.amjmed.2017.06.026 ; Raskob GE
Segers A
Angchaisuksiri P
Oh D
Boda Z
et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised
double-blind
double-dummy trial. Lancet Haematol. 2016;3:e379–87 ; Li A
Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res [Internet]. 2019;173:158–63. Available from: https://doi.org/10.1016/j.thromres.2018.02.144 ; Gobierno Nacional de Colombia. Decreto 2423 del 31 de 2006 - actualizado 2019. 2019 ; Husereau D
Drummond M
Petrou S
Carswell C
Moher D
Greenberg D
Pokaż więcej
Temat :
Rivaroxabán
Dalteparina
Cáncer
Tromboembolismo
Farmacoeconomía
Ciencias médicas
Medicina
Epidemiología
Dalteparin
Cancer
Thromboembolism
Pharmacoeconomics
Źródło :
reponame:Repositorio Institucional EdocUR ; instname:Universidad del Rosario ; Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73(11):1336–49 ; Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78–82 ; Khorana A, Francis C, Culakova E, Kuderer N, Lyman G. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost [Internet]. 2007;5:632–4. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L46680709%0Ahttp://dx.doi.org/10.1111/j.1538-7836.2007.02374.x%0Ahttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=15387933&id=doi:10.1111%2Fj.1538-7836.2007.02374.x&atitle=Thromboemb ; Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ. Epidemiology of venous thromboembolism in ....
Opis pliku :
application/pdf
Relacje :
https://repository.urosario.edu.co/handle/10336/20367
Dostępność :
https://doi.org/10.1111/j.1538-7836.2007.02374.x%0Ahttp://sfx.library.uu.nl/utrecht
https://doi.org/10.1016/j.thromres.2016.06.033
https://doi.org/10.1016/S0049-3848(14)50028-X
https://doi.org/10.1038/sj.bjc.6605599
https://doi.org/10.1016/j.ejca.2012.10.021
https://doi.org/10.1016/j.thromres.2012.10.007
https://doi.org/10.1183/16000617.0119-2018
https://doi.org/10.1016/S0049-3848(12)70033-6
https://doi.org/10.1016/S1470-2045(09)70232-3
https://doi.org/10.1016/j.thromres.2014.09.039
Dysertacja/Praca dyplomowa
Tytuł :
PCN284 - Compiling and Reconciling Evidence to Assign Risk of Febrile Neutropenia to Chemotherapy Regimens
Autorzy :
Egan, KS
Pokaż więcej
Źródło :
In Value in Health November 2016 19(7):A760-A760
Czasopismo naukowe
Tytuł :
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Autorzy :
Griffiths, RI
Barron, RL
Gleeson, ML
Danese, MD
O'Hagan, A
Chia, VM
Legg, JC
Lyman, GH
Pokaż więcej
Temat :
Humans
Breast Neoplasms
Neutropenia
Recombinant Proteins
Chemotherapy
Adjuvant
SEER Program
Least-Squares Analysis
Retrospective Studies
Long-Term Care
Age Factors
Costs and Cost Analysis
Health Care Costs
Hospitalization
Aged
80 and over
Continental Population Groups
Antineoplastic Combined Chemotherapy Protocols
Granulocyte Colony-Stimulating Factor
Kaplan-Meier Estimate
Medicare
United States
Female
Źródło :
Symplectic Elements at Oxford ; Europe PubMed Central ; PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) ; Scopus (http://www.scopus.com/home.url) ; Research Papers in Economics (http://repec.org/) ; CrossRef
Relacje :
uuid:1e4492fa-727e-414a-acdf-c0f2b4757dcd; urn:uuid:1e4492fa-727e-414a-acdf-c0f2b4757dcd; pii:3; local:359099; eissn:1179-2027; https://doi.org/10.2165/11589440-000000000-00000
Dostępność :
https://doi.org/10.2165/11589440-000000000-00000
Czasopismo naukowe
Tytuł :
PCN27 - Systematic Review Of The Efficacy And Safety Of Neurokinin-1 Receptor Antagonists For Chemotherapy-Induced Nausea And Vomiting: Identification Of The Relevant Clinical Trials
Autorzy :
Lyman, GH
Pokaż więcej
Źródło :
In Value in Health May 2016 19(3):A138-A138
Czasopismo naukowe
Tytuł :
PCN98 - Cost Effectiveness of Pegfilgrastim for Reducing Incidence of Febrile Neutropenia Events after Cytotoxic Chemotherapy for Solid Tumors in Turkey
Autorzy :
Saka, G
Pokaż więcej
Źródło :
In Value in Health May 2016 19(3):A151-A151
Czasopismo naukowe
Tytuł :
PHS83 - Over- And Underuse of Therapeutic and Palliative Care Services for Cancer Patients at End of Life: A Population-Based Study
Autorzy :
Ramsey, S
Pokaż więcej
Źródło :
In Value in Health May 2016 19(3):A24-A24
Czasopismo naukowe
Tytuł :
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
Autorzy :
Aapro, MS
Bohlius, J
Cameron, DA
Dal Lago, L
Donnelly, JP
Kearney, N
Lyman, GH
Pettengell, R
Tjan-Heijnen, VC
Walewski, J
Weber, DC
Zielinski, C
Pokaż więcej
Relacje :
http://epubs.surrey.ac.uk/827428/; Aapro, MS, Bohlius, J, Cameron, DA, Dal Lago, L, Donnelly, JP, Kearney, N, Lyman, GH, Pettengell, R, Tjan-Heijnen, VC, Walewski, J, Weber, DC and Zielinski, C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours EUROPEAN JOURNAL OF CANCER, 47 (1). pp. 8-32.
Dostępność :
https://doi.org/10.1016/j.ejca.2010.10.013
Czasopismo naukowe
Tytuł :
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action
Autorzy :
Khorana, Aa
Streiff, Mb
Farge, D
Mandala', M
Debourdeau, P
Cajfinger, F
Marty, M
Falanga, A
Lyman, Gh.
Pokaż więcej
Opis pliku :
STAMPA
Relacje :
info:eu-repo/semantics/altIdentifier/pmid/19720907; info:eu-repo/semantics/altIdentifier/hdl/11391/1480800; volume:27; issue:29; firstpage:4919; lastpage:4926; numberofpages:8; journal:JOURNAL OF CLINICAL ONCOLOGY; urn:ISSN:0732-183X; http://hdl.handle.net/11391/1480800; 2-s2.0-70350714641
Dostępność :
http://hdl.handle.net/11391/1480800
Czasopismo naukowe
Tytuł :
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
Autorzy :
Aapro, MS
Cameron, DA
Pettengell, R
Bohlius, J
Crawford, J
Ellis, M
Kearney, N
Lyman, GH
Tjan-Heijnen, VC
Walewski, J
Weber, DC
Zielinski, C
Pokaż więcej
Relacje :
http://epubs.surrey.ac.uk/827468/; Aapro, MS, Cameron, DA, Pettengell, R, Bohlius, J, Crawford, J, Ellis, M, Kearney, N, Lyman, GH, Tjan-Heijnen, VC, Walewski, J, Weber, DC and Zielinski, C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours EUROPEAN JOURNAL OF CANCER, 42 (15). pp. 2433-2453.
Dostępność :
https://doi.org/10.1016/j.ejca.2006.05.002
Czasopismo naukowe
Tytuł :
Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF
Autorzy :
Paridaens, Robert
Lyman, GH
Leonard, R.
Crawford, J
Bosly, André
Constenla, M.
Jackisch, C.
Pettengell, R.
Szucs, T
EJC - Supplements
Pokaż więcej
Temat :
breast cancer
adjuvant chemotherapy
neutropenia
filgrastim
pegfilgrastim
rHuG-CSF
Źródło :
EJC - Supplements, Vol. 1, no. 9, p. 1-12 (2003)
Relacje :
boreal:40087; http://hdl.handle.net/2078.1/40087; urn:ISSN:1359-6349
Dostępność :
https://doi.org/10.1016/S1359-6349(03)00082-X
http://hdl.handle.net/2078.1/40087
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies